Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NervGen Pharma ( (TSE:NGEN) ) has shared an update.
NervGen Pharma announced that it will present topline results from the chronic cohort of its Phase 1b/2a study of NVG-291 at the American Spinal Injury Association Annual Scientific Meeting. This study, which is a double-blind, placebo-controlled clinical trial, aims to demonstrate NVG-291’s potential for neural repair in individuals with spinal cord injury. The trial evaluates both clinical and electrophysiological assessments to characterize efficacy signals, with the hope of supporting further investigation of NVG-291 in spinal cord injury.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma is a clinical-stage biotechnology company focused on developing neuroreparative therapeutics. The company is working on innovative treatments to promote nervous system repair in cases of neurotrauma and neurologic diseases. Its lead candidate, NVG-291, is being tested for clinical efficacy in spinal cord injury, and preclinical evaluations are underway for another candidate, NVG-300, in models of ischemic stroke and spinal cord injury.
Average Trading Volume: 79,584
Technical Sentiment Signal: Buy
Current Market Cap: C$336.5M
For a thorough assessment of NGEN stock, go to TipRanks’ Stock Analysis page.